GRTS - Gritstone Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.72
+0.25 (+4.57%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.47
Open5.47
Bid5.63 x 1100
Ask0.00 x 900
Day's Range5.43 - 5.76
52 Week Range5.43 - 15.94
Volume112,757
Avg. Volume159,800
Market Cap211.505M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.81
Earnings DateMar 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.14
  • Earnings Update: Gritstone Oncology, Inc. Just Reported And Analysts Are Boosting Their Estimates
    Simply Wall St.

    Earnings Update: Gritstone Oncology, Inc. Just Reported And Analysts Are Boosting Their Estimates

    Shareholders in Gritstone Oncology, Inc. (NASDAQ:GRTS) had a terrible week, as shares crashed 28% to US$5.60 in the...

  • Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Misses Revenue Estimates
    Zacks

    Gritstone Oncology, Inc. (GRTS) Reports Q4 Loss, Misses Revenue Estimates

    Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -1.32% and -26.33%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Gritstone Oncology Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    EMERYVILLE, Calif., March 11, 2020 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies.

  • GlobeNewswire

    Gritstone Oncology to Present at Two Investor Conferences in March

    EMERYVILLE, Calif., Feb. 25, 2020 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight.

  • Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness
    TipRanks

    Analysts: 3 Healthcare Stocks to Buy on Coronavirus Weakness

    With the coronavirus outbreak spreading rapidly in countries beyond China, so is the fear among investors. Yesterday marked the S&P 500’s worst one-day performance since February 2018 as the index slipped 3%. The impacts were felt outside of the U.S. market as well; European markets dropped to their lowest point since 2016 and the sell-off continued in Asia.On Monday, investor concern spiked after Italy and South Korea reported that the number of infections had grown. South Korea, which stated that it could use emergency powers to aid its containment efforts, announced 231 new cases. In Italy, police and military forces locked down 11 towns and prohibited 50,000 people from movement as officials reported the number of cases reached 219.Baird’s chief investment strategist Bruce Bittles notes, “There was a cavalier attitude about the virus.” However, with the number of infections rising worldwide, he argues, “you have to think about the global economy slipping enough to cause a shortfall in earnings.”Having said that, there was a bright spot in yesterday’s doom and gloom as the World Health Organization reported that since February 2, new cases in China have been on the decline. Additionally, Wall Street analysts remind investors that safe-havens can be found as the broader market experiences weakness, specifically pointing to the healthcare sector.With this in mind, we used TipRanks’ Stock Screener tool to zero in on 3 healthcare stocks that have amassed enough bullish support from the analyst community to earn a “Strong Buy” consensus rating. Not to mention each boasts some serious upside potential from current levels. Let’s read out the data.Gritstone Oncology Inc. (GRTS)Gritstone Oncology is working to eradicate cancer with its personalized immunotherapies to fight multiple types of cancer. Unlike some of its peers, its unique approach focuses on the individual nature of tumors, triggering a therapeutic immune response by harnessing the natural power of a patient’s immune system to recognize tumor antigens. While shares have taken a tumble yesterday, Cowen analyst Marc Frahm still sees big things in store.After hosting a dinner with members of Gritstone’s management team as well as Columbia physician Dr. Charles Drake, the analyst came away more confident in its development programs. According to Dr. Drake, “emerging data from PD-1 studies makes it clear that while some long-term responders may achieve sterilizing immunity and therefore not need long-lived T cell memory, at least 20% of long-term responders are actually in a homeostatic state with persistent very low levels of disease being controlled by constant immune pressure.”As a result, an effective immuno-oncology (IO) therapy must produce a large amount of IFN-gamma producing cytotoxic CD8+ T cells to reduce tumor volumes. However, it’s challenging to figure out the precise number of T cells that are necessary, which in turn, makes it difficult to define a threshold that a vaccine must achieve.Taking all of this into consideration, Frahm tells investors that Dr. Drake believes Gritstone’s GRANITE and SLATE neoantigen vaccines are “impressive." The physician argues that in the cancer vaccine segment, both the magnitude and the quality of T cells being produced are unheard of. The analyst noted, “He attributes this to (1) the choice of a heterologous prime boost vaccination strategy, (2) the use of an AdV-vector for the priming step, and (3) the use of neoantigens rather than cancer testis antigens.”Bearing this in mind, Frahm sides with the bulls on this healthcare company. The four-star analyst reiterated an Outperform rating, but declined to set a price target on the stock. (To watch Frahm’s track record, click here)Out on Wall Street, the analysts are in agreement. With 100% Street support, 5 Buys (in the past 3 months) to be exact, the message is clear: GRTS is a Strong Buy. In addition, the $25.50 average price target suggests shares could soar 187% over the next year. (See Gritstone stock analysis on TipRanks)Epizyme, Inc. (EPZM)Epizyme specializes in epigenetics as well as small molecule inhibitor development. These molecules are designed to work against histone methyltransferases (HMTs), which play a significant part in gene expression regulation. While shares tumbled 13% yesterday on the back of the Coronavirus fears, Cowen analyst Yaron Werber believes that “Epizyme is a classic turnaround that is emerging from hardship.”Werber tells clients that Tazverik, its oral small molecule inhibitor of EZH2, is a significant component of his bullish thesis. The therapy, which was approved for an epithelioid sarcoma (ES) indication in January and launched at the beginning of this month, is de-risked following the FDA ruling. Adding to the good news, Tazverik was added to the National Comprehensive Cancer Network’s (NCCN) Clinical Practice Guidelines in Oncology as a recommended ES treatment. “We think that the NCCN guidelines inclusion will be highly positive for Tazverik to overcome the reimbursement barrier and accelerate the uptake in ES,” Werber commented.Additionally, EPZM filed an sNDA for the therapy’s use in patients with follicular lymphoma (FL), and is on target with the FDA’s Priority Review timeline for its June 18 PDUFA date. Based on clinical data, Werber argues that Tazverik’s oral dosing and “clean” safety profile make approval likely, with this new indication lending itself to possible gains.While some investors have expressed concern about the therapy’s use in FL, Werber remains confident. “Data in the bigger EZH2 WT is less robust but still approvable given the drug’s meaningful efficacy and clean safety profile. Concerns about partial clinical hold due to secondary malignancy in one patient are overdone and was addressed with labeling. We believe that the stock offers an attractive profile given the upside potential for this late stage asset,” he explained.As management stated it has $381.1 million in cash and a $50 million option sold to Royalty Pharma, the deal is sealed for Werber. However, in addition to maintaining his bullish call, the five-star analyst decreased the price target from $36 to $32. That being said, the target still leaves room for a twelve-month gain of 48%. (To watch Werber’s track record, click here)Turning now to the rest of the Street, other analysts also have high hopes for the healthcare name. Out of 8 reviews published in the last three months, 7 were bullish, making the consensus rating a Strong Buy. At $27.63, the average price target implies 28% upside potential. (See Epizyme stock analysis on TipRanks)Evelo Biosciences, Inc. (EVLO)Evelo Biosciences stock is another healthcare name that unfairly beaten down by the coronavirus. While share tumbled nearly 13% yesterday, the Street is still betting on EVLO.Using its integrated platform, Evelo Biosciences develops oral biologics that utilize the central role that cells in the small intestine play in various systems of the body. With this approach, the company has been able to design product candidates for several inflammatory diseases and cancer.The company has recently decided to discontinue its EDP1066 candidate in atopic dermatitis, and Chris Shibutani of Cowen sees EPD1815, the comapny's lead candidate in the psoriasis and atopic dermatitis indications, as possibly being able to show “clinical efficacy in inflammatory indications."The four-star analyst added, “We view this decision as prudent, given that EDP1815 showed preliminary activity in at least one indication (psoriasis). EVLO noted that the decision was not made on the basis of safety, but rather on the atopic dermatitis data. No meaningful safety issues have been identified with monoclonal microbials to date, to our knowledge.”On top of this, Shibutani is looking forward to updates on the Phase 1/2 trial of EDP1503 and pembrolizumab in the first half of 2020. Calling the data readout a potential catalyst, the analyst is hoping to see a response in patients with microsatellite stable colorectal cancer (MSS CRC), triple-negative breast cancer or other tumor types who have experienced a relapse on prior PD-1/L1 inhibitor treatment.Given all that EVLO has going for it, Shibutani left his Outperform rating unchanged. The analyst declined to issue a price target, though. (To watch Shibutani’s track record, click here)What does the rest of the Street have to say? It turns out that other analysts have also been impressed by EVLO. A Strong Buy consensus rating breaks down into 3 Buys and 1 Hold assigned in the last three months. Not to mention the $20 average price target puts the upside potential at a whopping 280%. (See Evelo stock analysis on TipRanks)

  • GlobeNewswire

    Gritstone Oncology to Present at the 38th Annual J.P. Morgan Healthcare Conference

    EMERYVILLE, Calif., Jan. 08, 2020 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight.

  • We Think Gritstone Oncology (NASDAQ:GRTS) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Gritstone Oncology (NASDAQ:GRTS) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Is Gritstone Oncology, Inc. (GRTS) A Good Stock To Buy?
    Insider Monkey

    Is Gritstone Oncology, Inc. (GRTS) A Good Stock To Buy?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]

  • Benzinga

    The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...

  • GlobeNewswire

    Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE

    -- Preliminary results demonstrate unprecedented levels of primed CD8+ neoantigen-specific cytotoxic T cells and expansion of pre-existing T cells even in low-dose cohorts ----.

  • GlobeNewswire

    Gritstone Oncology to Webcast a Review of the Clinical Immunogenicity Data from its Neoantigen-based Immunotherapies that will be Presented at the ESMO Immuno-Oncology Congress

    EMERYVILLE, Calif., Dec. 09, 2019 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight.

  • GlobeNewswire

    Gritstone Oncology to Present at the Piper Jaffray Annual Healthcare Conference

    EMERYVILLE, Calif., Nov. 26, 2019 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight.

  • Gritstone Oncology, Inc. (GRTS) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Gritstone Oncology, Inc. (GRTS) Reports Q3 Loss, Misses Revenue Estimates

    Gritstone Oncology, Inc. (GRTS) delivered earnings and revenue surprises of -13.24% and -18.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Gritstone Oncology Reports Third Quarter 2019 Financial Results and Recent Highlights

    EMERYVILLE, Calif., Nov. 12, 2019 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to.

  • Will Gritstone Oncology, Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will Gritstone Oncology, Inc. (GRTS) Report Negative Q3 Earnings? What You Should Know

    Gritstone Oncology, Inc. (GRTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy

    Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced data on novel shared tumor-specific neoantigens (TSNA) arising from recurrent cancer driver mutations that have been identified by its EDGE platform.

  • GlobeNewswire

    Gritstone Oncology to Webcast Investor Event Reviewing its Neoantigen-based Immunotherapies During SITC Conference

    Gritstone Oncology (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will webcast an investor event with its executive management team on Friday, November 8, 2019 from 6:00-8:00 p.m. ET. The event will focus on the company’s clinical-stage immunotherapies, GRANITE and SLATE, including an overview of the ongoing trials as well as the type of preliminary immunogenicity and safety data the company expects to have for presentation at the European Society for Medical Oncology’s Immuno-Oncology Congress (ESMO-IO) in December. The company will also review the novel shared neoantigens contained within its first SLATE product candidate that will be presented at the Society for Immunotherapy of Cancer (SITC) Conference in National Harbor, MD earlier that day.

  • GlobeNewswire

    Gritstone Oncology Announces Upcoming Presentation on Novel Shared Neoantigens Included within “Off-The-Shelf” SLATE Immunotherapy at SITC 2019 Annual Meeting

    Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it will present the novel shared neoantigens included within its first SLATE product candidate at the Society for Immunotherapy of Cancer (SITC) Conference in National Harbor, MD. SLATE is an investigational “off-the-shelf” immunotherapy directed at shared tumor-specific neoantigens (TSNA), derived from gene mutations frequently observed in cancer patients.

  • Investors Who Bought Gritstone Oncology (NASDAQ:GRTS) Shares A Year Ago Are Now Down 37%
    Simply Wall St.

    Investors Who Bought Gritstone Oncology (NASDAQ:GRTS) Shares A Year Ago Are Now Down 37%

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

  • GlobeNewswire

    Gritstone Oncology to Present at Cantor Global Healthcare Conference

    EMERYVILLE, Calif., Sept. 26, 2019 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to.

  • GlobeNewswire

    Gritstone Oncology Announces Changes to its Board of Directors, Including the Appointment of Biotech Veteran Dr. Elaine V. Jones

    Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced changes to its board of directors. Elaine V. Jones, Ph.D., has joined the company’s board, replacing Peter Svennilson, founder of the Column Group and co-lead Series A investor in Gritstone. “Elaine’s distinguished background in building and growing innovative biotech companies with two decades of life sciences venture capital experience, over 20 seats on life science company boards, and direct experience within biopharma research and business development, will bring a powerful perspective to our board of directors,” said Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer of Gritstone Oncology.

  • GlobeNewswire

    Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy

    Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of immunotherapies to fight multiple cancer types, today announced that the first SLATE patient has been dosed. SLATE is an investigational immunotherapy directed at shared tumor-specific neoantigens (TSNA) which are derived from driver mutations, functionally important gene alterations recurrently observed in cancer patients (such as KRAS). Gritstone has used its proprietary EDGETM artificial intelligence platform to identify the top twenty immunogenic shared TSNA to engineer into the cassette of its first SLATE immunotherapy.

  • GlobeNewswire

    Gritstone Oncology Reports Second Quarter 2019 Financial Results and Recent Highlights

    EMERYVILLE, Calif., Aug. 12, 2019 -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to.

  • GlobeNewswire

    Gritstone Oncology to Present at Two Upcoming Investor Conferences in June

    EMERYVILLE, Calif., June 05, 2019 -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight.